Wedbush maintains Zura Bio at Outperform, lowers price target to $10 from $22
Wedbush kept Zura Bio's rating at Outperform but reduced its price target from $22 to $10, a 54.5% cut. This implies a 144.5% upside from the Nov 6 close of $4.09, according to the firm.
How this was made

The 30-second read
Why it matters
Analyst target reduction reflects concerns about near-term growth prospects, likely prompting short-term price weakness.
Market read
The downgrade may trigger a sell-off in ZURA and influence sentiment in the broader biotech sector.
What to watch
Potential upcoming clinical data or partnership announcements could offset the downgrade.
Background
Zura Bio (NASDAQ: ZURA) is a clinical-stage biotech focused on oncology therapies.
Ticker impact
Wedbush lowered Zura Bio's price target from $22 to $10, indicating a significant downgrade.
likely downward pressure as investors price in the reduced target
Analyst downgrade with a 54.5% target reduction signals weaker expectations for the stock.
Market effects
May weigh on other small-cap biotech stocks as analysts reassess valuations.
Limited to US biotech sector.
Low, confined to niche biotech investors.
Counterpoint
Some investors may view the cut as an overreaction and see buying opportunity at the lower target.
Key entities
- AnalystWedbush Securities
Provided the rating maintenance and target cut.
- CompanyZura Bio Inc.
Subject of the analyst downgrade.
